Experts are urging the Indian government to implement national standard treatment guidelines for haemophilia, a genetic disorder that affects blood clotting. Currently, less than 20% of patients are diagnosed, leaving a staggering 80% undetected. This underdiagnosis is partly due to the condition's genetic nature and the challenges in early detection. Dr. Tulika Seth, a haematology professor at AIIMS in New Delhi, highlights that mild cases often go unnoticed until serious medical procedures reveal the deficiency. Misdiagnosis, particularly in children, can lead to inappropriate treatments and long-term joint damage. While traditional treatment has been reactive, recent advancements in non-factor therapies offer a preventive approach that is easier for patients. However, only about 4% of haemophilia patients in India currently receive prophylactic treatment, compared to 80-90% in high-income countries. Experts stress the importance of developing India-specific Standard Treatment Guidelines (STGs) to ensure uniform care, taking into account local resources and contexts. Implementing these guidelines could significantly enhance the quality of life for haemophilia patients and reduce disability across the nation.